425: Curaleaf Urges Aurora Shareholders to Tender Shares

Curaleaf Holdings, Inc. has issued a letter to Aurora Cannabis Inc. shareholders, encouraging them to accept Curaleaf's offer, which represents a 45% premium, and participate in the combined entity.

Summary

• Curaleaf Holdings, Inc. has sent a letter to Aurora Cannabis Inc. shareholders urging them to tender their shares as part of Curaleaf's acquisition offer.
• The offer represents a 45% premium over Aurora's share price prior to Curaleaf's offer.
• Curaleaf highlights the potential to create the world's leading cannabis company with operations in 17 countries.
• The combined entity is projected to have over $1.5 billion in trailing twelve-month revenue and nearly $350 million in adjusted EBITDA.
• Curaleaf anticipates at least $40 million in annual cost synergies.
• A live shareholder Q&A with Curaleaf Chairman and CEO Boris Jordan is scheduled for September 17, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for Curaleaf, as it represents a strategic move to acquire a competitor and expand market share, although the success hinges on Aurora shareholder acceptance.

Positives

• Curaleaf's offer provides Aurora shareholders with a 45% premium.
• The proposed combination would create the largest and most diversified global cannabis company.
• The combined entity is expected to generate over $1.5 billion in LTM revenue and nearly $350 million in LTM adjusted EBITDA.
• Anticipated annual cost synergies of at least $40 million.
• Aurora shareholders would gain exposure to Curaleaf's leading U.S. platform and potential benefits of regulatory reform.
• Curaleaf's shares have shown strong performance, increasing approximately 50% in the first six months of 2026, compared to Aurora's decline.

Negatives

• Aurora has been diluting its shareholders by raising over $400 million through equity issuances, with shares sold at prices significantly below Curaleaf's offer value.
• Aurora's management has guided revenue and adjusted EBITDA lower for the next year.
• Aurora's net revenue and adjusted EBITDA declined 14% and 78% respectively over the four quarters ended June 30, 2026, with operating cash flow turning negative.

Risks

• Failure to satisfy conditions to the Offer.
• Failure to realize anticipated synergies.
• Changes in general economic conditions.
• Fluctuations in foreign exchange and interest rates.
• Regulatory changes.
• The PSLRA safe harbor for forward-looking statements does not apply to statements made in connection with a tender offer.

Future Outlook

Curaleaf anticipates that the combination with Aurora will create the world's leading cannabis company with significant growth prospects and participation in the future upside of the largest, most diversified global cannabis platform. The company expects to realize at least $40 million in annual cost synergies. Aurora shareholders are encouraged to consider the future upside of the combined entity.

Management Comments

• "Aurora shareholders have an important choice to make. They can accept a 45% premium and become owners of the world's largest and most diversified cannabis company or remain invested in a shrinking business that is burning cash and getting less profitable by the day. We encourage shareholders to consider the facts, review the offer materials, and decide for themselves which path offers the greatest value."
• "Our Offer to buy Aurora and combine the two businesses delivers immediate value while allowing shareholders to participate in the future upside of the largest, most diversified global cannabis platform."
• "Together, Curaleaf and Aurora would create the global cannabis leader with operations across 17 countries, more than US$1.5 billion of last twelve-month revenue, nearly US$350 million of adjusted EBITDA and at least US$40 million of expected annual cost synergies."
• "We remain prepared to engage constructively. But Aurora has refused. And so, we are putting the decision where it belongs: in your hands."
• "We encourage you to consider the facts, review the Offer materials and tender your Aurora shares."

Industry Context

StockSavvy.ai notes that this filing represents a significant consolidation play within the cannabis industry, driven by Curaleaf's ambition to solidify its position as the global leader. The move comes amid ongoing regulatory evolution and a competitive landscape where scale and diversification are increasingly important for long-term success.

Comparison to Industry Standards

• Curaleaf's offer of a 45% premium is a substantial incentive, aiming to attract Aurora shareholders by providing immediate value and participation in a larger, more diversified entity.
• The projected combined revenue of over $1.5 billion and adjusted EBITDA of nearly $350 million would position the merged company at the forefront of the global cannabis market, surpassing many competitors in scale.
• The anticipated $40 million in annual cost synergies are a key driver for the acquisition, reflecting industry trends where operational efficiencies are crucial for profitability in a capital-intensive sector.
• Curaleaf's own share performance (up 50% in H1 2026) contrasts sharply with Aurora's decline (down 34% in H1 2026), highlighting Curaleaf's perceived stronger operational and market execution compared to Aurora's struggles.

Stakeholder Impact

• Shareholders: Aurora shareholders are offered a 45% premium and the opportunity to own shares in a larger, potentially more stable and profitable global cannabis company. Curaleaf shareholders may benefit from increased market share and synergies.
• Employees: Potential for workforce integration and restructuring following the acquisition, which could lead to both opportunities and redundancies.
• Creditors: The financial health and stability of the combined entity will be a key consideration for creditors of both companies.

Next Steps

• Aurora shareholders are encouraged to review the offer materials and tender their shares before the December 1, 2026 deadline.
• Curaleaf will host a live shareholder Q&A on September 17, 2026, for Aurora shareholders.
• Curaleaf is prepared to engage constructively with Aurora, though Aurora has reportedly refused engagement.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' for Curaleaf shareholders at this juncture. While the acquisition of Aurora is a strategic move to consolidate market leadership and achieve significant synergies, the success is contingent on Aurora shareholders accepting the offer. The integration process and realization of synergies carry inherent risks. For Aurora shareholders, the offer presents a compelling premium, but the decision to tender should weigh the immediate gain against potential long-term upside in a successful combined entity or a continued standalone turnaround for Aurora.

Keywords

cannabis acquisition, tender offer, shareholder letter, merger, Aurora Cannabis, Curaleaf Holdings, cannabis industry, corporate finance